Diabetic macular edema (DME), a vision-threatening manifestation of DR (Hu et al., 2024), commonly requires therapy with vascular endothelial growth factor inhibitors (VEGFis) (Hanna et al., 2022) and significantly contributes to diabetes-related visual impairment. Here, VEGFA is linked to diabetes mellitus.